Form DEFA14A Viking Therapeutics,
Tweet
Share
E-mail
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☒Filed by a party other than the Registrant ☐
Check the appropriate box:
☐Preliminary Proxy Statement
☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐Definitive Proxy Statement
☒Definitive Additional Materials
☐Soliciting Material under § 240.14a-12
Viking Therapeutics, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
☒No fee required
☐Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11
|
1. |
Title of each class of securities to which transaction applies: |
|
2. |
Aggregate number of securities to which transaction applies: |
|
3. |
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): |
|
4. |
Proposed maximum aggregate value of transaction: |
|
5. |
Total fee paid: |
|
|
|
☐Fee paid previously with preliminary materials.
|
☐ |
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
|
1. |
Amount Previously Paid: |
|
2. |
Form, Schedule or Registration Statement No.: |
|
3. |
Filing Party: |
|
4. |
Date Filed: |
|
|
|
ADDITIONAL INFORMATION REGARDING THE
ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON
THURSDAY, MAY 21, 2020
Viking Therapeutics, Inc. previously issued the following press release, which relates to its proxy statement dated April 6, 2020, and furnished to stockholders of the Company in connection with the solicitation of proxies by the Board of Directors of the Company for use at the 2020 Annual Meeting of Stockholders . This supplement is being filed with the Securities and Exchange Commission and is being made available to stockholders on May 20, 2020.
THIS SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH VIKING THERAPEUTICS, INC. PROXY STATEMENT DATED APRIL 6, 2020.
____________________________________________________________________________
SUPPLEMENT TO DEFINITIVE PROXY STATEMENT FOR
ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD THURSDAY, MAY 21, 2020
Viking Therapeutics Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting
SAN DIEGO, May 12, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced a change to its 2020 Annual Meeting of Stockholders. Due to conditions associated with the coronavirus pandemic (COVID-19), including restrictions on in-person gatherings, and in order to support the health and well-being of our stockholders and other meeting participants, Viking’s 2020 Annual Meeting of Stockholders will be held in a virtual meeting format only.
The previously announced date and time of the Annual Meeting, May 21, 2020, at 8:00 a.m. Pacific Time, will not change. There is also no change to the items of business to be addressed at the Annual Meeting, which are described in Viking’s proxy materials as previously distributed. The proxy materials are available at http://astproxyportal.com/ast/20061/.
As noted above, stockholders may not attend the Annual Meeting in person. Instead, stockholders should follow the instructions provided below to attend the virtual Annual Meeting. American Stock Transfer & Trust Company, LLC (AST) will host the virtual Annual Meeting and tabulate votes for the meeting.
Stockholders are encouraged to vote their shares prior to the virtual Annual Meeting by any of the methods described in the proxy materials. The proxy card and voting instruction form included with the previously distributed proxy materials will not be updated to reflect the change in the format of the meeting, but they may continue to be used to vote the shares on the proposals to be presented at the virtual Annual Meeting. Stockholders who have previously voted do not need to take any further action.
Instructions to Attend the Annual Meeting
Record Holders: Holders of record of Viking common stock at the close of business on March 31, 2020 (i.e., shares held in holder’s own name in the records of Viking’s transfer agent, AST), may attend the virtual Annual Meeting by visiting https://web.lumiagm.com/255403211 and entering the 11-digit control number in previously provided proxy materials. The password for the virtual Annual Meeting is viking2020. Stockholders of record who have misplaced their 11-digit control number, contact AST at (800) 973-5449.
Beneficial Owners: Beneficial owners of common stock of Viking at the close of business on March 31, 2020 (i.e., shares held in “street name" through an intermediary, such as a bank,
broker or other nominee), must register in advance to attend the virtual Annual Meeting. To register, beneficial owners must obtain a legal proxy from the bank, broker or other nominee that is the record holder of the shares and then submit the legal proxy, along with their name and email address, to AST to receive an 11-digit control number. This control number can then be used to access the virtual Annual Meeting site provided above. Please note that any control number that was previously provided with proxy materials, likely a 16-digit number, will not provide access to the virtual Annual Meeting site. All requests for registration and submission of legal proxies should be labeled as “Legal Proxy” and must be received by AST no later than 5:00 p.m. Pacific Time, on May 18, 2020. All requests should be submitted by email to [email protected], by facsimile to (718) 765-8730 or by mail to American Stock Transfer & Trust Company, LLC, Attn: Proxy Tabulation Department, 6201 15th Avenue, Brooklyn, NY 11219. Obtaining a legal proxy may take several days and stockholders are advised to register as far in advance as possible. Once an 11-digit control number is obtained from AST, please follow the steps set forth above for stockholders of record to attend the virtual Annual Meeting.
Technical Assistance
Participants are encouraged to access the Annual Meeting prior to the start time. Online check-in will begin at 7:30 a.m. Pacific Time. Please allow ample time for the check-in procedures. Technicians will be ready to assist with any technical difficulties prior to the start of the virtual Annual Meeting. Stockholders of record and beneficial owners should call AST at (800) 937-5449 with any questions regarding the virtual Annual Meeting. If you encounter any difficulty accessing the virtual Annual Meeting, please visit https://go.lumiglobal.com/faq for assistance.
The virtual Annual Meeting platform is fully supported across browsers (Internet Explorer, Firefox, Chrome and Safari) and devices (desktops, laptops, tablets and cell phones) running the most updated version of applicable software and plugins. Participants should ensure that they have a strong Internet connection wherever they intend to participate in the Annual Meeting. Participants should also give themselves ample time to log in and ensure that they can hear streaming audio prior to the start of the Annual Meeting.
About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed NASH and fibrosis. In a Phase 2 trial for the treatment of NAFLD and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of X-linked adrenoleukodystrophy (X-ALD).
Viking's other programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator (SARM). In a Phase 2 trial in patients recovering from hip fracture, patients who received VK5211 experienced significant improvements in measures of lean body mass compared with patients who received placebo. Other programs also include earlier-stage programs targeting metabolic diseases and anemia. The company holds exclusive worldwide
rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.
Follow Viking on Twitter @Viking_VKTX.
Contacts:
Viking Therapeutics
Michael Morneau
858-704-4660
Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
Tim Brons (Media)
415-675-7402
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Therapeutics (VKTX) Tops Q1 EPS by 2c
- Methanex Reports on Annual General Meeting of Shareholders and Welcomes Roger Perreault to Its Board of Directors
- ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Shoals Technologies Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SHLS
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
